DFIB Cardiac Science (MM)

Cardiac Science to Present at UBS Global Life Sciences Conference IRVINE, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading U.S. manufacturer of life-saving automated public-access defibrillators (AEDs), announced today that Chairman and CEO Raymond W. Cohen is scheduled to make an investor presentation at the UBS Global Life Science Conference at 2:30 pm EDT on Thursday, September 30, 2004. The conference runs from September 27-30, 2004 at the Grand Hyatt in New York City. The presentation will be webcast and management encourages shareholders and other interested parties to listen to the live webcast by going to the company's website at http://www.cardiacscience.com/. About Cardiac Science Cardiac Science develops, manufactures and markets Powerheart(R)-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The Company also makes the Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies. For more information, please visit http://www.cardiacscience.com/, email Cardiac Science at or call 1-949-797-3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the Company, or its representatives, have made or may make forward-looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward-looking statements. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2003, subsequent quarterly filings, and other documents filed by the Company with the Securities and Exchange Commission. For more information please contact: Matt Clawson (Investors) Len Hall (Media) Allen & Caron Inc. (949) 474-4300 or Roderick de Greef Chief Financial Officer Cardiac Science, Inc. 949-797-3800 DATASOURCE: Cardiac Science, Inc. CONTACT: investors, Matt Clawson, , or media, Len Hall, , both of Allen & Caron Inc. for Cardiac Science, Inc., +1-949-474-4300; or Roderick de Greef, Chief Financial Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright